May 12, 2022 / 12:00PM GMT
Operator
Good day, and welcome to the Cullinan Oncology, Taiho Collaboration Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Chad Messer the Investor Vice President of Investor Relations of Cullinan Oncology. Please go ahead, sir.
Chad Messer -
Hello, everyone, and thank you all for joining us to discuss our strategic collaboration with Taiho for the joint development and commercialization of CLN-081. My name is Chad Messer, and I'm the Vice President of Investor Relations at Cullinan Oncology.
Before we begin, I would like to remind you all of the safe harbor provisions outlined on Slide 2. During today's presentation, management will be making certain forward-looking statements which are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties, which may cause actual results to differ materially from those contained in such forward-looking statements. These risks are described more fully in the company's filings made with the
Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call Transcript
May 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers